Abstract
BackgroundTocilizumab (TCZ), an inhibitor of interleukin-6 (IL-6), has been widely used to treat rheumatic diseases such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis. Recently, TCZ was approved for use...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have